Qiagen N.V.
QGEN | NYSE
$50.37
+$0.15 (+0.30%)
Nov 2, 2026, 12:14 PM ET · Market open
Company Profile
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Key Executives
| Name | Position |
|---|---|
| Jonathan Pratt | CEO & Member of Management Board |
| Roland Sackers | Chief Financial Officer, MD & Member of Management Board |
| Antonio Santos | Senior Vice President & Head of Global Operations |
| Daniel Wendorff CEFA CIIA | VP & Head of Investor Relations |
| Jean-Pascal Viola | Senior Vice President & Head of Corporate Strategy and Business Development |
| John Gilardi | Vice President & Head of Corporate Communications |
| Michael Scheffler | Vice President & Head of Global Sample Technologies |
| Nitin Sood | Senior VP & Head of Product Portfolio & Innovation |
| Stephany Foster | Senior Vice President & Head of Human Resources |
| Thierry Bernard | Member of Management Board |
| Thomas Schweins | Senior Vice President of Life Science Business Area |
| Thomas Theuringer | Senior Director & Head of External Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 09, 2026 | 6-K | Filing |
| Aug 07, 2026 | 6-K | Filing |
| Aug 07, 2026 | 6-K | Filing |
| Aug 07, 2026 | 6-K | Filing |
| Jun 05, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jun 01, 2026 | SD | Filing |
| May 08, 2026 | 6-K | Filing |
| May 08, 2026 | 6-K | Filing |
| Mar 20, 2026 | IRANNOTICE | Filing |
| Mar 20, 2026 | 20-F | Filing |
Qiagen N.V.
| Country | Netherlands |
| IPO Date | Jun 28, 1996 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 5,500 |
| CEO | Jon Pratt |
Stock Details
| Ticker Symbol | QGEN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001015820 |
| CUSIP Number | n/a |
| ISIN Number | NL0015002SN0 |
| SIC Code | 2836 |
Recent News
- 2 days ago / zacks.comDo Options Traders Know Something About Qiagen Stock We Don't?
- 5 days ago / zacks.comQiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
- 11 days ago / globenewswire.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: QIAGEN N.V. (NYSE – QGEN), Varonis Systems, Inc. (Nasdaq – VRNS), CCC Intelligent Solutions Holdings Inc. (Nasdaq – CCC), Penske Automotive Group, Inc. (NYSE – PAG)
- 11 days ago / benzinga.comThis Qiagen Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
- 12 days ago / businesswire.comQIAGEN reports preliminary Q3 2026 results
- 20 days ago / businesswire.comQIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis
- 27 days ago / businesswire.comQIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery
- 1 month ago / zacks.comQIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel
- 1 month ago / businesswire.comQIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel
- 1 month ago / businesswire.comQIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation
Add to Watchlist
Select watchlists to add or remove QGEN